Competition for human estrogen receptors
Biochemical assay · Human ERα- or ERβ-containing cell extracts [1]
Glycitein displaced radiolabeled estradiol, with stronger apparent binding to ERβ than ERα and weaker binding than estradiol. This is a binding assay, not a treatment-efficacy test.
| Endpoint | Reported result | Reference |
|---|---|---|
| Displacement of receptor-bound [3H]-17β-estradiol | Qualitative concentration-response Binding observed at both subtypes; greater apparent affinity for ERβ. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Variable competitor concentrations, plotted as fold excess of estradiol in Figure 5A; 2.5 pmol radiolabeled estradiol in 250 μL assay mixture.
- Exposure duration
- 16 h
- Method
- Cell-free competition assay at 0 °C.
- Co-treatment
- Glycitein tested as a competitor of radiolabeled estradiol, not a drug combination.
- Reported limits
- Vehicle not specified in the competition subsection; no fitted glycitein IC50 or Ki supplied. Receptor-free extract and testosterone specificity results are described as data not shown.
Methods and source locations
Compound reported in the paper: Glycitein; Compound label in the paper: GLE; filled triangles in Figure 5
Evidence concerns the paper’s isolated glycitein; no validation of an Adooq lot.
Figure 1, p. 352; Competition Assay of Isoflavone, p. 352; specificity controls, p. 353; Figure 5A and Results, p. 354
Displacement of receptor-bound [3H]-17β-estradiol: Radioligand competition with charcoal separation and scintillation counting. — Figure 5A, p. 354; Competition Assay of Isoflavone, p. 352; specificity controls, p. 353